Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 340 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Human regular insulin Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans

NCT03077360
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes, Obesity
Interventions
Lifestyle
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COMIDAS Comparing Original Mexican Diets and Standard US Diets

NCT01369173
View directory record Official record
Conditions
Healthy
Interventions
Mexican or American foods
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

NCT00979875
View directory record Official record
Conditions
Healthy
Interventions
Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 4 Interventional Results available

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

NCT03336528
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Degludec, Glargine, Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 2 Interventional Results available

Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)

NCT00596934
View directory record Official record
Conditions
Fatty Liver Disease, Nonalcoholic
Interventions
metreleptin
Drug
Lead sponsor
Elif Oral
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

NCT03298867
View directory record Official record
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 8, 2026, 10:31 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

NCT00630552
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer
Interventions
Placebo, AMG 479, AMG 655
Other · Drug
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
44
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 8, 2026, 10:31 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 8, 2026, 10:31 PM EDT
Recruiting Phase 1 Interventional

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

NCT07341373
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Portal Insulin U-500, Humulin R U-500, Lyumjev U-100 Insulin
Drug
Lead sponsor
Portal Diabetes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

NCT00803972
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rHuPH20, Insulin Human Injection, Insulin Lispro Injection
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 8, 2026, 10:31 PM EDT
Terminated Not applicable Interventional Results available

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

NCT02701257
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 8, 2026, 10:31 PM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile Intravenous (IV) Insulin on Wound Healing in Diabetics

NCT00967837
View directory record Official record
Conditions
Wound Healing, Diabetes
Interventions
Pulsatile Intravenous Insulin Therapy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 8, 2026, 10:31 PM EDT
Active, not recruiting Phase 3 Interventional

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06334133
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Granada Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

NCT00949663
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Sep 8, 2026, 10:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenetics of Muscle Insulin Resistance

NCT03259984
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 1 Interventional

Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I

NCT02371226
View directory record Official record
Conditions
Mucopolysaccharidosis I
Interventions
AGT-181 (HIRMAb-IDUA)
Drug
Lead sponsor
ArmaGen, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Oakland, California • Orange, California • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 1 Interventional

VRS-317 in Adult Subjects With Growth Hormone Deficiency

NCT01359488
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Sep 8, 2026, 10:31 PM EDT
Withdrawn Phase 2 Interventional

Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome

NCT00654667
View directory record Official record
Conditions
Insulin Resistance
Interventions
Placebo, Resveratrol
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 8, 2026, 10:31 PM EDT
Withdrawn Not applicable Interventional

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.

NCT00720616
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Norditropin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

NCT00896298
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Phase 1 Interventional

Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma

NCT02507583
View directory record Official record
Conditions
Malignant Glioma, Neoplasms
Interventions
IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.
Drug
Lead sponsor
david andrews
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adipose Tissue Response to Overfeeding in Insulin Resistance-Prone vs. Insulin Sensitive Humans

NCT02084641
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Over feeding
Other
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 8, 2026, 10:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity in Overweight Girls: Implications for Reversing Risk Factors for Type 2 Diabetes

NCT01323088
View directory record Official record
Conditions
Abdominal Obesity, Physical Activity
Interventions
Control, Resistance Exercise, Aerobic exercise
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2013 · Synced Sep 8, 2026, 10:31 PM EDT